Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Centene Corporation (CNC) SEC Filings & Earnings Calls

EquiReason read 19 Centene Corporation SEC filings in the last 12 months. Latest: 8-K on 2026-10-08 — Centene Corporation redeemed all $568.7M of its 4.25% Notes due 2027, reducing debt and interest expense..

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

CNCCentene CorporationFollow CNC — free
Healthcare Plans · Healthcare
—
Price chart with a free account
Market cap
34.7B
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
27 Oct, in 3 days

Every filing, read

last 12 months · SEC

What happened, the numbers inside, guidance and risks. The original is one click away.

8 Oct 20268-K · 8.01Centene Corporation redeemed all $568.7M of its 4.25% Notes due 2027, reducing debt and interest expense.open

Risks flagged

No new risk introduced; debt reduction is credit positive.

Read the original on SEC EDGAR ↗
16 Sep 20268-K · 7.01Centene reaffirms full year 2026 GAAP diluted EPS guidance >$3.11 and adjusted diluted EPS >$4.80 at Deutsche Bank Healthcare Summit.open

Figures in the filing · each found in the filing text

GAAP diluted EPS · FY2026$3.11
Adjusted diluted EPS · FY2026$4.80

Guidance

FY26 GAAP diluted EPS >$3.11; FY26 adjusted diluted EPS >$4.80

Reaffirms full year 2026 EPS guidance.

Read the original on SEC EDGAR ↗
17 Aug 20268-K · 5.02, 7.01Adjusted diluted EPS guidance $4.80; Guidance: Adjusted diluted EPS > $4.80open

Figures in the filing · each found in the filing text

Adjusted diluted EPS guidance · FY2026$4.80

Guidance

Adjusted diluted EPS > $4.80

Full year 2026 adjusted diluted EPS guidance reaffirmed at >$4.80.

Risks flagged

CFO transition risk; orderly but key leadership change.

“CFO stepping down; successor named with transition period.”
Read the original on SEC EDGAR ↗
29 Jul 20268-K · 8.01Centene redeems $500M of 4.25% Notes due 2027; reduces debt and interest expense; $568.7M remains outstanding.SEC ↗
28 Jul 202610-QCentene reported Q2 2026 results with revenue growth and significant margin improvement.earningsopen

Figures in the filing · each found in the filing text

Managed care membership · Q2-202625,885,400-8% y/y
Total revenues · Q2-2026$53.58B+10% y/y
Premium and service revenues · Q2-2026$44.38B+4% y/y
Health benefits ratio (HBR) · Q2-202689.6%
SG&A expense ratio · Q2-20267.0%
Adjusted SG&A expense ratio · Q2-20266.9%
GAAP diluted earnings per share · Q2-2026$2.19
Adjusted diluted earnings per share · Q2-2026$2.51
Operating cash flow · Q2-2026$3.60B
Medicaid total revenues · Medicaid · Q2-2026$31.97B+14% y/y

Risks flagged

Medicaid Membership Decline

“Managed care membership of 25.9 million, a decrease of 2.1 million members, or (8)% year-over-year.” · word for word

Regulatory Policy Uncertainty

“The OBBBA, passed in July 2025, includes requirements that may reduce the number of members eligible for state Medicaid Expansion programs by requiring work or community engagement by members and for state Medicaid agencies to redetermine member eligibility at more frequent intervals, along with adding a "Cost Sharing" or "Co-Pay" for certain medical service”

California UIS Transition

“Effective January 1, 2027, the State of California will transition the Medi-Cal Unsatisfactory Immigration Status (UIS) population from managed care to the fee-for-service delivery system. As a result, we expect a reduction in California Medicaid membership and associated premium revenue beginning in 2027.” · word for word

Contract Protest Risk

“Further, we are in the process of protesting the results of Medicaid procurement awards in Georgia and Texas. If these protests are not successful, our future results of operations would be impacted.” · word for word
Read the original on SEC EDGAR ↗
28 Jul 20268-K · 2.02, 5.02, 7.01Total revenues $53.58B; Premium and service revenues $44.38B (+4% y/y); Health benefits ratio 89.6; Guidance: GAAP EPS >$3.11, Adjusted EPS >$4.80earningsopen

Figures in the filing · each found in the filing text

Total revenues · Q2-2026$53.58B
Premium and service revenues · Q2-2026$44.38B+4% y/y
Health benefits ratio · Q2-202689.6%
GAAP diluted earnings per share · Q2-2026$2.19
Adjusted diluted earnings per share · Q2-2026$2.51
Total cash flow provided by operations · Q2-2026$3.59B
Total at-risk membership · Q2-202625,885,400-8% y/y

Guidance

GAAP EPS >$3.11, Adjusted EPS >$4.80

Raised full-year EPS guidance; strong earnings beat; margin improvement.

Risks flagged

Membership decline, particularly in Marketplace and Medicaid.

“Total at-risk membership 25.9M vs 28.0M; Marketplace 3.5M vs 5.9M.”

Guidance includes ~$0.50 of non-recurring items.

“Guidance increase resulting from underlying strength of the business, including approximately $0.50 of non-recurring items in Medicare and Commercial segments.” · word for word
Read the original on SEC EDGAR ↗
22 Jun 20268-K · 5.02, 7.01Reported the departure of a director or principal officer (CEO/CFO change); issued a Regulation FD disclosure (forward guidance or material update)SEC ↗
15 May 20268-K · 5.02, 5.07Reported the departure of a director or principal officer (CEO/CFO change); submitted matters to a vote of security holdersSEC ↗
28 Apr 20268-K · 2.02Total revenues $49.94B; Premium and service revenues $44.66B (+5% y/y); Health benefits ratio 87.3; Guidance: FY2026 adjusted diluted EPS guidance raised to >$3.40; GAAP diluted EPS >$2.37earningsopen

Figures in the filing · each found in the filing text

Total revenues · Q1-2026$49.94B
Premium and service revenues · Q1-2026$44.66B+5% y/y
Health benefits ratio · Q1-202687.3%
Adjusted diluted earnings per share · Q1-2026$3.37
GAAP diluted earnings per share · Q1-2026$3.11
Total cash flow provided by operations · Q1-2026$4.37B
Debt reduction · Q1-2026$1.00B
Medicaid HBR · Medicaid · Q1-202693.1%
Medicare HBR · Medicare · Q1-202684.9%
Total at-risk membership · Q1-202626,272,900-6% y/y

Guidance

FY2026 adjusted diluted EPS guidance raised to >$3.40; GAAP diluted EPS >$2.37

Raised FY2026 EPS guidance on strong Q1 results, Medicaid margin recovery, and Medicare outperformance.

Risks flagged

Marketplace membership decline of 36% YoY; higher acuity among Silver Tier members.

“Marketplace membership 3,582,200 vs 5,626,000 prior year; Commercial HBR of 75.3%, slightly above expectations, primarily reflecting higher acuity among Marketplace Silver Tier members.”

Medicaid membership decline of 4% YoY.

“Total Medicaid membership 12,426,900 vs 12,958,800 prior year.”
Read the original on SEC EDGAR ↗
28 Apr 202610-QTotal Revenues $49.94B (+7% y/y); Premium and Service Revenues $44.66B (+5% y/y); Health Benefits Ratio (HBR) 87.3open

Figures in the filing · each found in the filing text

Total Revenues · Q1-2026$49.94B+7% y/y
Premium and Service Revenues · Q1-2026$44.66B+5% y/y
Health Benefits Ratio (HBR) · Q1-202687.3%
Adjusted Diluted EPS · Q1-2026$3.37+16% y/y
GAAP Diluted EPS · Q1-2026$3.11+18% y/y
Operating Cash Flow · Q1-2026$4.37B+189% y/y
Net Earnings Attributable to Centene · Q1-2026$1.54B+18% y/y
Medicaid Gross Margin · Medicaid · Q1-2026$1.62B+13% y/y
Medicare Gross Margin · Medicare · Q1-2026$1.55B+29% y/y
Commercial Gross Margin · Commercial · Q1-2026$2.36B-7% y/y

Risks flagged

Medicaid Redetermination Membership Decline

“Since March 31, 2023, eligibility redeterminations are the primary driver of our Medicaid membership decline.” · word for word

Elevated Medical Cost Trend

“We continue to observe and respond to elevated medical cost trend impacting the industry in recent years.” · word for word

Marketplace Regulatory and Membership Risk

“The combined effect of the expiration of the Enhanced APTCs and the Final Rule reduced 2026 Marketplace membership in the first quarter compared to 2025.” · word for word

Contract Protest and Procurement Risk

“Further, we are in the process of protesting the results of Medicaid procurement awards in Georgia and Texas. If these protests are not successful, our future results of operations would be impacted.” · word for word

Federal Securities Class Action

“On July 9, 2025, a putative federal securities class action... was filed against the Company and certain of its executives... The plaintiffs... allege that the Company made false and misleading statements with respect to the Company's 2025 earnings guidance.” · word for word
Read the original on SEC EDGAR ↗
26 Mar 2026DEF 14ATotal Revenues $194.80B (+19% y/y); Adjusted Diluted EPS $2.08 (-70% y/y); GAAP Diluted Loss Per Share $-13.53open

Figures in the filing · each found in the filing text

Total Revenues · FY2025$194.80B+19% y/y
Adjusted Diluted EPS · FY2025$2.08-70% y/y
GAAP Diluted Loss Per Share · FY2025$-13.53
Premium and Service Revenues · FY2025$174.60B
Membership · 2025-12-3127,600,000
Cash and Investments · 2025-12-31$38.80B
Adjusted Net Earnings · FY2025$1.00B
Adjusted Pre-Tax Net Earnings · FY2025$1.30B

Risks flagged

Marketplace Morbidity Risk

“Led the industry in understanding the implications of the changes in morbidity of the Marketplace population that we became aware of late in the second quarter of 2025 and took corrective pricing actions for 2026 in states covering 95% of Marketplace membership.” · word for word

Medicaid Rate Pressure

“Advocated with our Medicaid state partners for increases in rates to reflect more recent experience.” · word for word

Regulatory and Legal Risk

“In August 2025, several law firms, including Hagens Berman, announced a class-action lawsuit against Centene and its executives.” · word for word

Medicare Profitability Risk

“Strategically designed our 2026 Medicare Advantage bid and pricing strategy with a focus on profitability.” · word for word
Read the original on SEC EDGAR ↗
24 Mar 20268-K · 5.02Base salary for new CAO $440,000.00; target bonus percentage for new CAO 60open

Figures in the filing · each found in the filing text

base salary for new CAO$440000.00
target bonus percentage for new CAO60.0%
Read the original on SEC EDGAR ↗
10 Mar 20268-K · 7.01, 8.01Centene redeemed $1B of 4.25% Notes due 2027, leaving ~$1.19B outstanding. Also reaffirmed FY2026 GAAP EPS >$1.98 and adjusted EPS >$3.00 at a conference.open

Figures in the filing · each found in the filing text

GAAP diluted EPS guidance · FY2026$1.98
Adjusted diluted EPS guidance · FY2026$3.00

Guidance

FY2026 GAAP diluted EPS >$1.98; adjusted diluted EPS >$3.00

Reaffirmed FY2026 EPS guidance at a conference; no change from prior.

Risks flagged

Debt redemption reduces outstanding notes but uses cash; remaining $1.19B notes still outstanding.

“Following the redemption, approximately $1,186,664,000 of the 2027 Notes will remain outstanding.” · word for word
Read the original on SEC EDGAR ↗
23 Feb 20268-K · 7.01GAAP diluted EPS $1.98; Adjusted diluted EPS $3.00; Guidance: GAAP diluted EPS >$1.98, adjusted diluted EPS >$3.00open

Figures in the filing · each found in the filing text

GAAP diluted EPS · FY2026$1.98
Adjusted diluted EPS · FY2026$3.00

Guidance

GAAP diluted EPS >$1.98, adjusted diluted EPS >$3.00

Reaffirms 2026 EPS guidance, no change from prior.

Risks flagged

No new risks disclosed; standard forward-looking cautionary language.

“Standard risk factor language, no specific new risks.”
Read the original on SEC EDGAR ↗
17 Feb 202610-KMedicaid membership 12,500,000; Marketplace membership 5,500,000; Medicare Advantage membership 1,000,000open

Figures in the filing · each found in the filing text

Medicaid membership · Medicaid · 2025-12-3112,500,000
Marketplace membership · Marketplace · 2025-12-315,500,000
Medicare Advantage membership · Medicare Advantage · 2025-12-311,000,000
Medicare PDP membership · Medicare PDP · 2025-12-318,100,000
Consolidated indebtedness · 2025-12-31$17.40B
Impairment charges on pending divestiture · Magellan Health · FY2025$513M

Risks flagged

Medical cost trend acceleration

“In 2025, we have experienced an accelerated increase in medical cost trend. The drivers of this trend include increasing medical demand, expanded access to care facilitated by program changes at the state level, and the rapid release and availability of new, high-cost pharmaceuticals.” · word for word

Regulatory and legislative changes reducing enrollment and increasing morbidity

“The OBBBA, passed in July 2025, includes requirements that may reduce the number of members eligible for state Medicaid Expansion programs by requiring work or community engagement by members and for state Medicaid agencies to redetermine member eligibility at more frequent intervals” · word for word

High debt level

“As of December 31, 2025, we had consolidated indebtedness of $17.4 billion.” · word for word

Pending divestiture execution risk

“In December 2025, we signed a definitive agreement to divest the remaining Magellan Health businesses. As a result, we recorded non-cash impairment charges associated with the pending divestiture totaling $513 million, or $389 million after-tax.” · word for word

Marketplace rate filing risk

“If the states increase the tax rates applicable to our Marketplace line of business during 2026, we cannot offset those increases by increasing premiums, as our Marketplace rates were approved and determined in 2025, which could have a material impact on the profitability of our Marketplace products” · word for word
Read the original on SEC EDGAR ↗
6 Feb 20268-K · 2.02Total revenues $194.78B; Premium and service revenues $174.58B (+20% y/y); Health benefits ratio 91.9; Guidance: 2026 adjusted diluted EPS >$3.00 vs 2025 $2.08earningsopen

Figures in the filing · each found in the filing text

Total revenues · FY2025$194.78B
Premium and service revenues · FY2025$174.58B+20% y/y
Health benefits ratio · FY202591.9%
Adjusted diluted EPS · FY2025$2.08
Total at-risk membership · FY202527,633,500+7% y/y
Marketplace membership · Marketplace · FY20255,541,400+26% y/y
Medicaid membership · Medicaid · FY202512,518,400-4% y/y
Medicare PDP membership · Medicare PDP · FY20258,118,600+17% y/y
Operating cash flow · FY2025$5.09B

Guidance

2026 adjusted diluted EPS >$3.00 vs 2025 $2.08

2026 adjusted diluted EPS guidance >$3.00 implies ~44% growth from 2025 $2.08; management cites momentum from actions in H2 2025.

Risks flagged

Magellan divestiture impairment and ongoing restructuring risk.

“Non-cash impairment charges $513M associated with pending Magellan divestiture.”

Medicaid membership decline of 4% YoY; HBR volatility in Commercial segment.

“Medicaid membership down from 13.0M to 12.5M; Q4 Commercial HBR 95.4% 100bps above expectations.”
Read the original on SEC EDGAR ↗
10 Nov 20258-K · 7.01GAAP diluted loss per share (guidance) $-12.85; Adjusted diluted EPS (guidance) $2.00; Guidance: GAAP diluted loss per share not to exceed $(12.85); adjusted diluted EPS at least $2.00open

Figures in the filing · each found in the filing text

GAAP diluted loss per share (guidance) · FY2025$-12.85
Adjusted diluted EPS (guidance) · FY2025$2.00

Guidance

GAAP diluted loss per share not to exceed $(12.85); adjusted diluted EPS at least $2.00

Reaffirmed full year 2025 guidance; no change from prior outlook.

Risks flagged

GAAP loss guidance indicates significant non-cash charges or impairments; adjusted EPS low relative to GAAP loss.

“GAAP diluted loss per share not to exceed $(12.85) vs adjusted diluted EPS of at least $2.00.”
Read the original on SEC EDGAR ↗
29 Oct 20258-K · 2.02Total revenues $49.69B; Premium and service revenues $44.90B (+22% y/y); Health benefits ratio 92.7; Guidance: FY2025 adjusted diluted EPS at least $2.00, up $0.25earningsopen

Figures in the filing · each found in the filing text

Total revenues · Q3-2025$49.69B
Premium and service revenues · Q3-2025$44.90B+22% y/y
Health benefits ratio · Q3-202592.7%
SG&A expense ratio · Q3-20257.0%
GAAP diluted loss per share · Q3-2025$-13.50
Adjusted diluted earnings per share · Q3-2025$0.50
Total cash flow provided by operations · Q3-2025$1.36B
Total at-risk membership · Q3-202527,968,100+8% y/y
Medicaid membership · Medicaid · Q3-202512,706,400-3% y/y
Marketplace membership · Marketplace · Q3-20255,828,100+30% y/y

Guidance

FY2025 adjusted diluted EPS at least $2.00, up $0.25

Raised adjusted EPS guidance despite impairment and HBR pressure, indicating confidence in underlying operations and cost management.

Risks flagged

Massive goodwill impairment of $6.7B indicates potential overpayment for past acquisitions and reduces equity base.

“$6.7 billion non-cash goodwill impairment, resulting in a GAAP loss and corresponding reduction of retained earnings” · word for word

Elevated Medicaid HBR of 93.4% driven by behavioral health and home health costs; retroactive revenue adjustment provides only temporary benefit.

“Medicaid HBR of 93.4% in the third quarter, including an approximate 40 basis point benefit from a retroactive revenue adjustment” · word for word

Marketplace medical cost increase and lower risk adjustment revenue pressuring HBR.

“increased Marketplace medical costs, lower Marketplace estimated risk adjustment revenue” · word for word

IRA program changes impacting PDP business profitability.

“program changes in the PDP business as a result of the Inflation Reduction Act (IRA)” · word for word
Read the original on SEC EDGAR ↗
29 Oct 202510-QCentene reported Q3 2025 results with a $6.7B goodwill impairment, HBR up 350 bps YoY, and reduced 2025 earnings expectations due to higher medical costs and lower risk adjustment revenue.earningsopen

Figures in the filing · each found in the filing text

Membership · Q3-202527,968,100-2% y/y
Total Revenues · Q3-2025$49.69B+18% y/y
Premium and Service Revenues · Q3-2025$44.90B+22% y/y
Health Benefits Ratio (HBR) · Q3-202592.7%
SG&A Expense Ratio · Q3-20257.0%
Adjusted Diluted EPS · Q3-2025$0.50-69% y/y
Operating Cash Flow · 9M-2025$4.65B+528% y/y
Goodwill Impairment · Q3-2025$6.72B
Medicaid Membership · Medicaid · Q3-202512,706,400-3% y/y
Marketplace Membership · Commercial · Q3-20255,828,100+30% y/y

Guidance

Reduced 2025 earnings expectations due to lower risk adjustment revenue and higher medical costs

Centene reduced 2025 earnings expectations due to lower risk adjustment revenue and higher medical costs, with corrective pricing actions for 2026.

Risks flagged

Medicaid Redetermination Membership Decline

“Since March 31, 2023, redeterminations are the primary driver of our Medicaid membership decline.” · word for word

Marketplace Morbidity and Risk Adjustment Pressure

“We completed the process of refiling 2026 policy year rates during the third quarter of 2025 to reflect a higher projected baseline of Marketplace morbidity than previously expected.” · word for word

Medicare Advantage Premium Deficiency Reserve

“The premium deficiency reserve was increased to $270 million in the first quarter of 2025, to $389 million in the second quarter of 2025 and decreased by $107 million to $282 million in the third quarter of 2025 based on the progression of earnings during the year (with higher earnings at the beginning of the year and lower at the end of the year, given cost” · word for word

OBBBA Medicaid Expansion Impact

“The OBBBA, passed in July 2025, includes requirements that may reduce the number of members eligible for state Medicaid Expansion programs by requiring work or community engagement by members and for state Medicaid agencies to redetermine member eligibility at more frequent intervals, along with adding a 'Cost Sharing' or 'Co-Pay' for certain medical service” · word for word

Marketplace APTC Expiration Membership Decline

“We anticipate that the combined effect of the expiration of the enhanced APTCs, the Final Rule, and the OBBBA will reduce 2026 Marketplace membership and continue to increase the overall morbidity of the Marketplace population.” · word for word
Read the original on SEC EDGAR ↗

Centene Corporation — questions

What did Centene Corporation file recently?
19 SEC filings in the last 12 months. Latest: 8-K on 2026-10-08 — Centene Corporation redeemed all $568.7M of its 4.25% Notes due 2027, reducing debt and interest expense.

Every figure on this page comes from Centene Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.